Print Share

Secukinumab Dosage

Medically reviewed by Drugs.com. Last updated on June 18, 2020.

Applies to the following strengths: 150 mg/mL

Usual Adult Dose for:

Plaque Psoriasis
Psoriatic Arthritis
Ankylosing Spondylitis

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Precautions
Dialysis
Other Comments

Usual Adult Dose for Plaque Psoriasis

300 mg subcutaneously at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks (each 300 mg dose is given as 2 subcutaneous injections of 150 mg); for some patients, a dose of 150 mg subcutaneously may be acceptable

Use: Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy

Usual Adult Dose for Psoriatic Arthritis

WITH A LOADING DOSE: 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
WITHOUT A LOADING DOSE: 150 mg subcutaneously every 4 weeks; if the patient continues to have active psoriatic arthritis, consider increasing the dose to 300 mg subcutaneously every 4 weeks

Comments:
-For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosage for plaque psoriasis.
-This drug may be administered with or without methotrexate.

Use: Active psoriatic arthritis

Usual Adult Dose for Ankylosing Spondylitis

WITH A LOADING DOSE: 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
WITHOUT A LOADING DOSE: 150 mg subcutaneously every 4 weeks

Uses:
-For active ankylosing spondylitis
-For the treatment of active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Each injection should be administered at a different anatomic location (such as upper arms, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.
-This drug is intended for use under the supervision of a physician. Patients may self-inject after proper training in subcutaneous injection technique using the Sensoready pen or prefilled syringe.
-The lyophilized powder for reconstitution is for healthcare provider use only.

Reconstitution/preparation techniques:
-The lyophilized powder should be prepared and reconstituted with sterile water for injection using aseptic technique and without interruption.
-The preparation time from piercing the stopper until end of reconstitution on average takes 20 minutes and should not exceed 90 minutes.
-Refer to the manufacturer product information.

Storage requirements:
-Sensoready pens, prefilled syringes, and vials should be refrigerated at 2C to 8C (36F to 46F).
-Keep the product in the original carton to protect from light until the time of use. -Do not freeze.
-To avoid foaming do not shake.
-This drug does not contain a preservative; discard any unused portion.

General:
-Evaluate patients for tuberculosis (TB) infection prior to initiating this drug.

Patient advice:
-Read the patient leaflet thoroughly before use.
-The Sensoready Pens contain latex.
-The Sensoready Pens should not be shaken.